Celularity, Inc. (CELU)
1.68
-0.15
(-8.20%)
USD |
NASDAQ |
Sep 04, 16:00
1.70
+0.02
(+1.19%)
After-Hours: 20:00
Celularity Research and Development Expense (Quarterly) : 1.92M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2025 | 1.92M |
| September 30, 2025 | 3.15M |
| June 30, 2025 | 1.89M |
| March 31, 2025 | 2.262M |
| December 31, 2024 | 2.328M |
| September 30, 2024 | 2.396M |
| June 30, 2024 | 2.26M |
| March 31, 2024 | 4.233M |
| December 31, 2023 | |
| September 30, 2023 | 3.392M |
| June 30, 2023 | 6.828M |
| March 31, 2023 | 15.13M |
| Date | Value |
|---|---|
| December 31, 2022 | 9.104M |
| September 30, 2022 | 18.51M |
| June 30, 2022 | 23.58M |
| March 31, 2022 | 19.93M |
| December 31, 2021 | 22.63M |
| September 30, 2021 | 21.97M |
| June 30, 2021 | 21.53M |
| March 31, 2021 | 15.60M |
| December 31, 2020 | 12.64M |
| September 30, 2020 | 9.705M |
| June 30, 2020 | |
| March 31, 2020 | 11.11M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Tenax Therapeutics, Inc. | 12.85M |
| Exicure, Inc. | 0.174M |
| Century Therapeutics, Inc. | 16.98M |
| Absci Corp. | 22.62M |
| Cardio Diagnostics Holdings, Inc. | 0.1629M |